GEVO at a glance
Gevo, Inc. (GEVO, SEC CIK 1392380) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 26, 2026 and Form 4 insider filings as recently as September 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Gevo, Inc. (GEVO) reported revenue of $160.6 million (up 849.3% from FY2024) and a net loss of $33.8 million. Diluted EPS was -$0.14.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Gevo, Inc. (GEVO) shares worth $94.2 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Bloom Paul D on September 3, 2026 of 1,514 shares at $1.71 per share.
- In the last 90 days, GEVO insiders reported 2 open-market purchases ($96K) and 7 open-market sales ($476K) on Form 4, a net sale of $380K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $160.6M
- +849.3% vs prior year
- Insiders · 90 days
- 2 buys · 7 sells
- Net −$380K
- 13F holders
- 25 funds
- $94.2M · +0 vs prior quarter
- Latest 8-K
- Aug 26, 2026
- Item 7.01 · Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $46.5M, up 7% YoY from $43.4M, led by GevoND revenue of $40.5M versus $37.2M
- Gross margin 42.6% vs 43.6% YoY, with gross profit $19.8M versus $18.9M
- Worst segment Gevo, revenue $1.5M, down 22% YoY from $2.0M
- Operating loss $171.7M versus operating income $5.8M, including $135.8M impairment and $39.8M deposit-credit allowance
- ATJ-30 engineering continues through 2026; DOE loan-guarantee application withdrawn in April 2026
Risk Factors
- No Risk Factors section provided in the submitted excerpt
- No basis to identify newly added or materially updated risks versus the 10-K
- Rule 10b5-1 plan adopted by director Andrew Marsh for up to 396,946 shares
AI summary of the GEVO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Reg FD section contains only incorporation-by-reference and Section 18 liability disclaimers
- No substantive business, operating, financial, or market-moving disclosure in the provided text
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Greg Hanselman appointed Chief Operating Officer effective August 20, 2026
- Promotion expands responsibilities after serving as Executive Vice President, Operations and Engineering since January 2026
Item 2.02: Results of Operations and Financial Condition
- Gevo reported financial results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the substantive financial details
Item EX-99.1: Item EX-99.1
- Q2 revenue $46.5M, up from $43.4M; adjusted EBITDA $11.1M, down from $17.3M
- Full-year adjusted EBITDA outlook raised above $60M from $30M, supported by Canada CFR credits and Section 45Z monetization
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Todd Werpy appointed Class II independent director effective August 20, 2026, serving through the 2027 annual meeting
- Annual director compensation includes $85,000 cash retainer and $94,500 equity grant
Item 7.01: Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, not filed under Exchange Act Section 18
- Disclosure excluded from Section 18 liability and not incorporated into other Securities Act or Exchange Act filings
Item EX-99.1: Item EX-99.1
- Todd Werpy appointed to Gevo’s Board, effective August 20, 2026
- Former ADM Chief Science Officer adds expertise in biotechnology, catalysis, process engineering, and commercialization
AI summaries of GEVO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for GEVO
Don't miss the next GEVO filing
- Alerts as it files. A push when GEVO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut GEVO, by share count.
- Ask anything. An AI agent that reads every GEVO filing and answers with sources.
GEVO alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Bloom Paul D | Sell | Sep 3, 2026 | 1,514 | $1.71 |
| Gruber Patrick R. | Sell | Sep 3, 2026 | 3,333 | $1.70 |
| Bowron Kimberly T | Sell | Sep 3, 2026 | 1,221 | $1.71 |
| Barber James J | Buy | Aug 21, 2026 | 50,000 | $1.54 |
| Kettner David Michael | Buy | Aug 21, 2026 | 12,500 | $1.55 |
| Werpy Todd Allen | A | Aug 20, 2026 | 62,583 | - |
| Bloom Paul D | M | Aug 13, 2026 | 50,000 | $1.18 |
| Bloom Paul D | M | Aug 13, 2026 | 50,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $16.9M | $160.6M |
| Operating Income | - | -$90.8M | -$20.2M |
| Net Income | -$66.2M | -$78.6M | -$33.8M |
| Op. Margin | - | -536.9% | -12.6% |
| Net Margin | - | -464.9% | -21.1% |
| Balance Sheet | |||
| Total Assets | - | $583.9M | $718.9M |
| Equity | $557.4M | $489.5M | $466.3M |
| ROE | -11.9% | -16.1% | -7.3% |
| Per Share | |||
| EPS | $-0.28 | $-0.34 | $-0.14 |
| Cash Flow | |||
| Operating CF | - | -$57.4M | -$13.4M |
| CapEx | $54.5M | $51.1M | $30.1M |
Source: XBRL data in Gevo, Inc. (GEVO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate GEVO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $94.2M |
| Q1 2026 | 25 | $163.4M |
| Q4 2025 | 25 | $116.0M |
| Q3 2025 | 25 | $104.2M |
| Q2 2025 | 23 | $61.7M |
| Q1 2025 | 19 | $32.2M |
| Q4 2024 | 16 | $55.9M |
| Q3 2024 | 11 | $10.7M |
- State Street Corp+4.36M (+48%)
- Invesco Ltd+2.23M (+66%)
- BlackRock+1.01M (+6%)
- Vanguard Portfolio Management LLC+370.0K (+7%)
- Northern Trust+142.9K (+8%)
- Goldman Sachs Group−2.37M (-61%)
- Citadel Advisors LLC−853.4K (-41%)
- Morgan Stanley−418.5K (-60%)
- Two Sigma Investments−106.1K (-27%)
- AQR Capital Management−33.5K (-55%)
- Millennium Management+447.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 169 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
GEVO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 8-K | Aug 26, 2026 | - | Analysis | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | May 29, 2026 | - | - |
Related Health Care companies
- CDXS · CODEXIS, INC.Industrial Organic Chemicals
- FF · FutureFuel Corp.Industrial Organic Chemicals
- GPRE · Green Plains Inc.Industrial Organic Chemicals
- REX · REX AMERICAN RESOURCES CorpIndustrial Organic Chemicals
- SXT · SENSIENT TECHNOLOGIES CORPIndustrial Organic Chemicals
- VGAS · Verde Clean Fuels, Inc.Industrial Organic Chemicals
- SAFX · XCF Global, Inc.Industrial Organic Chemicals
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
GEVO SEC filings: frequently asked questions
Are GEVO insiders buying or selling?
In the last 90 days, Gevo, Inc. (GEVO) officers, directors and 10% owners reported 2 open-market purchases worth $96,369 by 2 insiders and 7 open-market sales worth $476,121 by 4 insiders on Form 4, a net sale of $379,753. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold GEVO stock?
As of June 30, 2026, the largest Gevo, Inc. (GEVO) holders among the 13F filers tracked by SignalX were BlackRock ($27.5 million), State Street Corp ($20.1 million), Vanguard Capital Management LLC ($15.4 million), Invesco Ltd ($8.4 million), Vanguard Portfolio Management LLC ($8.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was GEVO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Gevo, Inc. (GEVO) reported revenue of $160.6 million (up 849.3% from FY2024) and a net loss of $33.8 million. Diluted EPS was -$0.14. The figures come from the XBRL data in the 10-K.
What did GEVO report in its latest 8-K?
Gevo, Inc. (GEVO) filed an 8-K on August 26, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Reg FD section contains only incorporation-by-reference and Section 18 liability disclaimers.
What are the latest GEVO SEC filings?
Gevo, Inc. (GEVO) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 26, 2026 and a Form 4 insider filing on September 4, 2026.
What is GEVO's SEC CIK number?
Gevo, Inc. (GEVO)'s SEC Central Index Key (CIK) is 1392380. EDGAR lists every GEVO filing under that number.
Ask anything about GEVO
The research agent reads GEVO's filings, financials, insider trades and 13F holders, then answers with sources.